×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TNXP – tonix pharmaceuticals holding corp. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TNXP
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/6
07:00 am
tnxp
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
Low
Report
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
12/30
08:12 am
tnxp
Tonix prices 615,025 shares at $16.26 in registered direct offering [Yahoo! Finance]
Medium
Report
Tonix prices 615,025 shares at $16.26 in registered direct offering [Yahoo! Finance]
12/29
08:12 am
tnxp
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering [Yahoo! Finance]
12/29
08:01 am
tnxp
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) [Yahoo! Finance]
12/29
07:57 am
tnxp
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
Medium
Report
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
12/29
07:45 am
tnxp
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Medium
Report
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
12/16
07:51 am
tnxp
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
04:15 pm
tnxp
tonix pharmaceuticals holding corp.
IN-LINE
Report
4.7%
tonix pharmaceuticals holding corp.
8/11/2025
04:15 pm
tnxp
tonix pharmaceuticals holding corp.
MISS
Report
1.3%
tonix pharmaceuticals holding corp.
5/12/2025
04:30 pm
tnxp
tonix pharmaceuticals holding corp.
BEAT
Report
5.8%
tonix pharmaceuticals holding corp.
5/12/2025
04:30 pm
tnxp
tonix pharmaceuticals holding corp.
BEAT
Report
5.8%
tonix pharmaceuticals holding corp.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/31
04:10 pm
tnxp
Form SCHEDULE 13G Tonix Pharmaceuticals Filed by: Point72 Asset Management, L.P.
Medium
Report
Form SCHEDULE 13G Tonix Pharmaceuticals Filed by: Point72 Asset Management, L.P.
12/29
04:44 pm
tnxp
Form 8-K Tonix Pharmaceuticals For: Dec 29
Low
Report
Form 8-K Tonix Pharmaceuticals For: Dec 29
12/29
04:42 pm
tnxp
Form 424B5 Tonix Pharmaceuticals
Low
Report
Form 424B5 Tonix Pharmaceuticals
12/29
07:46 am
tnxp
Form 8-K Tonix Pharmaceuticals For: Dec 29
Low
Report
Form 8-K Tonix Pharmaceuticals For: Dec 29
12/16
07:05 am
tnxp
Form 8-K Tonix Pharmaceuticals For: Dec 16
Low
Report
Form 8-K Tonix Pharmaceuticals For: Dec 16
12/9
07:34 am
tnxp
Form 8-K Tonix Pharmaceuticals For: Dec 09
Low
Report
Form 8-K Tonix Pharmaceuticals For: Dec 09
11/24
11:24 am
tnxp
Form 8-K Tonix Pharmaceuticals For: Nov 24
Low
Report
Form 8-K Tonix Pharmaceuticals For: Nov 24
11/21
04:49 pm
tnxp
Form 424B5 Tonix Pharmaceuticals
Medium
Report
Form 424B5 Tonix Pharmaceuticals
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/26
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)
80.0%
3/20 Form 8-K Tonix Pharmaceuticals For: Mar 19 70.2%
12/11 Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL 22.2%
9/5 Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 19.7%
2/4 Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences 18.1%
5/21 Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology 16.0%
11/15 Tonix Pharmaceuticals Prices $9.0 Million Public Offering 15.4%
2/28 Form 424B5 Tonix Pharmaceuticals 15.3%
3/23 Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit 15.1%
1/24 Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL 14.8%
3/20 Form 8-K Tonix Pharmaceuticals For: Mar 19 70.2%
12/11 Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL 22.2%
9/5 Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 19.7%
2/4 Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences 18.1%
5/21 Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology 16.0%
11/15 Tonix Pharmaceuticals Prices $9.0 Million Public Offering 15.4%
2/28 Form 424B5 Tonix Pharmaceuticals 15.3%
3/23 Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit 15.1%
1/24 Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL 14.8%
TOP News Decliners
2/5
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD
-48.5%
2/7 Form EFFECT Tonix Pharmaceuticals -39.5%
2/27 Form 4 Tonix Pharmaceuticals For: Feb 25 Filed by: MORRIS JESSICA EDGAR -37.6%
11/4 Form 8-K Tonix Pharmaceuticals For: Nov 04 -31.9%
3/24 Form 8-K Tonix Pharmaceuticals For: Mar 24 -26.0%
11/15 Form EFFECT Tonix Pharmaceuticals -25.0%
11/20 Tonix Pharma up 12% after hours on advancement of TNX-102 SL in AUD [Seeking Alpha] -22.7%
1/7 Tonix Pharmaceuticals to Present at Biotech Showcase 2020 -20.5%
7/15 Form S-1/A Tonix Pharmaceuticals -19.3%
11/25 Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference -18.6%
2/7 Form EFFECT Tonix Pharmaceuticals -39.5%
2/27 Form 4 Tonix Pharmaceuticals For: Feb 25 Filed by: MORRIS JESSICA EDGAR -37.6%
11/4 Form 8-K Tonix Pharmaceuticals For: Nov 04 -31.9%
3/24 Form 8-K Tonix Pharmaceuticals For: Mar 24 -26.0%
11/15 Form EFFECT Tonix Pharmaceuticals -25.0%
11/20 Tonix Pharma up 12% after hours on advancement of TNX-102 SL in AUD [Seeking Alpha] -22.7%
1/7 Tonix Pharmaceuticals to Present at Biotech Showcase 2020 -20.5%
7/15 Form S-1/A Tonix Pharmaceuticals -19.3%
11/25 Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference -18.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: